With regard to other models of skeletal muscle atrophy, HET has been reported to improve muscle atrophy by suppressing Atrogin-1 and activating AMPK in a disuse-induced muscle atrophy model (Yakabe et al., 2022), by suppressing IL-6 production in colon 26 adenocarcinoma (Yae et al., 2012), and inhibiting inflammation and oxidative stress in an amyotrophic lateral sclerosis mouse model (Cai and Yang, 2019). The gene discussed is FBXO32; the disease is muscle atrophy.